Femme et Homme
- | Pays :
- Spain
- United States
- Canada
- Les 2 autres...
- | Organes : -
- | Spécialités : -
Extrait
This open-label, parallel group study will evaluate the pharmacokinetics and safety of trastuzumab emtansine in patients with HER2-positive metastatic breast cancer and normal or reduced hepatic function. Patients will receive trastuzumab emtansine intravenously on Day 1 of each 3-week cycle. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.
Critère d'inclusion
- Breast Cancer